Diatreme Resources (ASX:DRX) is an emerging Australian producer of mineral and silica sands based in Brisbane. Our key projects comprise the Northern Silica Project and Galalar Silica Sand Project in Far North Queensland, located next to the world's biggest silica sand mine at Cape Flattery.
Copyright 2024 – Finance News Network
Source: Finance News Network
16 Oct 2024 - Rita Gatt, National Lead Partner - Regulation, Security and Risk at Deloitte, discusses the revolutionary potential of quantum computing.
Read More12 Jul 2023 - Regan Saveall, CEO of leading UK CBD company Dragonfly Biosciences, discusses the company and its plans to list on the ASX in August.
Read More06 Sep 2023 - Daniel Ortisi, Equity Research Analyst at Stock Doctor, discusses the winners and losers from reporting season and gives advice on portfolio positioning for FY24.
Read More11 May 2023 - Sayona Mining Limited (ASX:SYA) Finance Manager Dougal Elder provides an update on the company, discussing commercial production, the offtake agreement with Piedmont, the PFS for the lithium carbonate refinery, the upgrade of the Moblan resource, and the timeline for lithium hydroxide production.
Read More10 Oct 2023 - Tim Wither - Managing Director - Maximus Resources (ASX:MXR) is a gold and nickel exploration company.
Read More30 Jul 2021 - Novatti Group Limited (ASX:NOV) CEO, Peter Cook, provides an update on activities from the company's June quarter, discussing growth in platforms and infrastructure and the recent capital raise.
Read More21 Jun 2022 - BluGlass Limited (ASX:BLG) President Jim Haden discusses shipping an alpha product to a customer, and the development roadmap for the company.
Read More04 Mar 2024 - Dean Tuck - Managing Director - Dreadnought Resources (ASX:DRE) is a highly active West Australian mineral explorer focused on finding the metals needed now and in the future.
Read More31 Mar 2021 - Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q) CEO and Managing Director James Graham talks about progress with the company's lead anti-infective candidate Recce 327, its expanding portfolio of synthetic anti-infectives targeting viral pathogens and a broad range of bacteria, clinical trial results and priorities for 2021.
Read More06 Nov 2019 - Immutep Limited (ASX:IMM) CEO, Marc Voigt provides an update on the company's clinical trial data for its Phase 1 trial in melanoma, TACTI-mel, where patients are responding positively to the combination therapy of efti and Keytruda.
Read More
